This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Timothy G. Murray, MD

Arch Ophthalmol. 1997;115(12):1577-1578.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS ISSUE of the ARCHIVES, the Collaborative Ocular Melanoma Study (COMS) Group reports on factors that are predictive of growth and treatment of small choroidal melanomas based on data generated from their small-tumor observational study.¹ Their article sets the stage for an ongoing debate in the evaluation and management of patients with presumed small choroidal melanomas.

Uveal melanoma is the most common primary intraocular malignant neoplasm in adults. The management of patients with this malignancy has been a topic of controversy for decades. In 1985 the National Eye Institute,joined by the National Cancer Institute in 1991, funded the COMS Group to evaluate the treatment of choroidal melanoma.² The COMS was structured in 3 protocols: 2 randomized clinical trials to evaluate treatment of medium and large choroidal melanomas and a third, nonrandomized study of small choroidal melanomas.³ The large-tumor treatment trial compared fractionated external beam radiotherapy prior . . . [Full Text PDF of this Article]

Author Affiliations
Miami, Fla

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?